Εμφανίζονται 1 - 14 Αποτελέσματα από 14 για την αναζήτηση '"трициклические антидепрессанты"', χρόνος αναζήτησης: 0,57δλ Περιορισμός αποτελεσμάτων
  1. 1
  2. 2
  3. 3
    Academic Journal

    Συγγραφείς: V. A. Parfenov, В. А. Парфенов

    Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 2 (2023); 4-9 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 2 (2023); 4-9 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-2

    Περιγραφή αρχείου: application/pdf

    Relation: https://nnp.ima-press.net/nnp/article/view/1987/1506; Liu G, Yang X, Xue T, et al. Is Fluoxetine Good for Subacute Stroke? A Meta-Analysis Evidenced From Randomized Controlled Trials. Front Neurol. 2021 Mar 22;12:633781. doi:10.3389/fneur.2021.633781; Романов ДВ, Петелин ДС, Волель БА. Депрессии в неврологической практике. Медицинский совет. 2018;(1):38-45. doi:10.21518/2079-701X-2018-1-38-45.; Мосолов СН. Клиническое применение современных антидепрессантов. Санкт-Петербург: Медицинское информационное агентство; 1995. 568 с.; Elzib H, Pawloski J, Ding Y, Asmaro K. Antidepressant pharmacotherapy and poststroke motor rehabilitation: A review of neurophysiologic mechanisms and clinical relevance. Brain Circ. 2019 Apr-Jun;5(2):62-7. doi:10.4103/bc.bc_3_19. Epub 2019 Jun 27.; Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011 Feb;10(2):123-30. doi:10.1016/S1474-4422(10)70314-8. Epub 2011 Jan 7. Erratum in: Lancet Neurol. 2011 Mar;10(3):205.; Savadi Oskouie D, Sharifipour E, Sadeghi Bazargani H, et al. Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial. Neurorehabil Neural Repair. 2017 Jul;31(7):638-47. doi:10.1177/1545968317704902. Epub 2017 Apr 28.; FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet. 2019 Jan 19;393(10168):265-74. doi:10.1016/S0140-6736(18)32823-X. Epub 2018 Dec 5.; Kalbouneh HM, Toubasi AA, Albustanji FH, et al. Safety and Efficacy of SSRIs in Improving Poststroke Recovery: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2022 Jul 5;11(13):e025868. doi:10.1161/JAHA.122.025868. Epub 2022 Jun 22.; D'Anci KE, Uhl S, Oristaglio J, et al. Treatments for Poststroke Motor Deficits and Mood Disorders: A Systematic Review for the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Stroke Rehabilitation. Ann Intern Med. 2019 Dec 17;171(12):906-15. doi:10.7326/M19-2414. Epub 2019 Nov 19.; Galts CPC, Bettio LEB, Jewett DC, et al. Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neurosci Biobehav Rev. 2019 Jul;102:56-84. doi:10.1016/j.neubiorev.2019.04.002. Epub 2019 Apr 15.; Weintraub D, Rosenberg PB, Drye LT, et al; DIADS-2 Research Group. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010 Apr;18(4):332-40. doi:10.1097/JGP.0b013e3181cc0333; Cumbo E, Cumbo S, Torregrossa S, Migliore D. Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer's Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study. J Prev Alzheimers Dis. 2019;6(3):192-7. doi:10.14283/jpad.2019.24; Takemoto M, Ohta Y, Hishikawa N, et al. The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP). J Alzheimers Dis. 2020;76(2):769-72. doi:10.3233/JAD-200247; Elsworthy RJ, Aldred S. Depression in Alzheimer's Disease: An Alternative Role for Selective Serotonin Reuptake Inhibitors? J Alzheimers Dis. 2019;69(3):651-61. doi:10.3233/JAD-180780; Perini G, Cotta Ramusino M, Sinforiani E, et al. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat. 2019 May 10;15:1249-58. doi:10.2147/NDT.S199746; Heser K, Bleckwenn M, Wiese B, et al; AgeCoDe Study Group. Late-Life Depressive Symptoms and Lifetime History of Major Depression: Cognitive Deficits are Largely Due to Incipient Dementia rather than Depression. J Alzheimers Dis. 2016 Aug 1;54(1):185-99. doi:10.3233/JAD-160209; Галкин АС, Васильева СН, Симуткин ГГ и др. Изменение когнитивных функций у пациентов с депрессивными расстройствами в процессе терапии селективными ингибиторами обратного захвата серотонина. Современная терапия психических расстройств. 2021;(1):2-7. doi:10.21265/PSYPH.2021.78.55.001; Connors MH, Quinto L, Brodaty H. Longitudinal outcomes of patients with pseudodementia: a systematic review. Psychol Med. 2019 Apr;49(5):727-37. doi:10.1017/S0033291718002829. Epub 2018 Oct 15.; Goodarzi Z, Mrklas KJ, Roberts DJ, et al. Detecting depression in Parkinson disease: A systematic review and meta-analysis. Neurology. 2016 Jul 26;87(4):426-37. doi:10.1212/WNL.0000000000002898. Epub 2016 Jun 29.; Hsu YT, Liao CC, Chang SN, et al. Increased Risk of Depression in Patients with Parkinson Disease: A Nationwide Cohort Study. Am J Geriatr Psychiatry. 2015 Sep;23(9):934-40. doi:10.1016/j.jagp.2014.10.011. Epub 2014 Nov 6.; Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008 Apr 30;23(6):850-7. doi:10.1002/mds.21966; Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009 Mar 10;72(10):886-92. doi:10.1212/01.wnl.0000336340.89821.b3. Epub 2008 Dec 17.; Richard IH, McDermott MP, Kurlan R, et al; SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012 Apr 17;78(16):1229-36. doi:10.1212/WNL.0b013e3182516244. Epub 2012 Apr 11.; Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S. Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord. 2015 Aug;21(8):833-42; discussion 833. doi:10.1016/j.parkreldis.2015.04.018. Epub 2015 May 16.; Orayj K, Almeleebia T, Vigneshwaran E, et al. Trend of recognizing depression symptoms and antidepressants use in newly diagnosed Parkinson's disease: Population-based study. Brain Behav. 2021 Aug;11(8):e2228. doi:10.1002/brb3.2228. Epub 2021 Jun 14.; Jones CD, Motl R, Sandroff BM. Depression in multiple sclerosis: Is one approach for its management enough? Mult Scler Relat Disord. 2021 Jun;51:102904. doi:10.1016/j.msard.2021.102904. Epub 2021 Mar 18.; Fiest KM, Walker JR, Bernstein CN, et al; CIHR Team Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord. 2016 Jan;5:12-26. doi:10.1016/j.msard.2015.10.004. Epub 2015 Oct 19.; Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001 Dec;69(6):942-9.; Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008 Jan-Feb;30(1):40-8. doi:10.1016/j.genhosppsych.2007.08.002; Stubbs B, Koyanagi A, Thompson T, et al. The epidemiology of back pain and its relationship with depression, psychosis, anxiety, sleep disturbances, and stress sensitivity: Data from 43 low- and middle-income countries. Gen Hosp Psychiatry. 2016 Nov-Dec;43:63-70. doi:10.1016/j.genhosppsych.2016.09.008. Epub 2016 Sep 30.; Gerrits MMJG, van Oppen P, van Marwijk HWJ, et al. Pain and the onset of depressive and anxiety disorders. Pain. 2014 Jan;155(1):53-9. doi:10.1016/j.pain.2013.09.005. Epub 2013 Sep 6.; Hung CI, Liu CY, Fu TS. Depression: An important factor associated with disability among patients with chronic low back pain. Int J Psychiatry Med. 2015;49(3):187-98. doi:10.1177/0091217415573937. Epub 2015 Apr 30.; Kolber MR, Ton J, Thomas B, et al. PEER systematic review of randomized controlled trials: Management of chronic low back pain in primary care. Can Fam Physician. 2021 Jan;67(1):e20-e30. doi:10.46747/cfp.6701e20; Urquhart DM, Wluka AE, van Tulder M, et al. Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial. JAMA Intern Med. 2018 Nov 1;178(11):1474-81. doi:10.1001/jamainternmed.2018.4222. Erratum in: JAMA Intern Med. 2019 Mar 1;179(3):457.; Парфенов ВА, Исайкин АИ. Боли в поясничной области. Москва; 2018.; Amiri S, Behnezhad S, Azad E. Migraine headache and depression in adults: a systematic review and meta-analysis. Neuropsychiatr. 2019 Sep;33(3):131-40. doi:10.1007/s40211-018-0299-5. Epub 2019 Jan 21.; Asif N, Patel A, Vedantam D, et al. Migraine With Comorbid Depression: Pathogenesis, Clinical Implications, and Treatment. Cureus. 2022 Jun 16;14(6):e25998. doi:10.7759/cureus.25998; Rampello L, Alvano A, Chiechio S, et al. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology. 2004;50(4):322-8. doi:10.1159/000080960; MacGregor EA, Frith AA, Hackshaw A. Efficacy, safety, and tolerability of sertraline on depressive symptoms in women with comorbid migraine: an open-label study. J Clin Psychopharmacol. 2011 Jun;31(3):392-3. doi:10.1097/JCP.0b013e3182189d70; Curone M, Tullo V, Savino M, et al. Outcome of patients with chronic migraine with medication overuse and depression after duloxetine: influence of coexisting obsessive compulsive disorder. Neurol Sci. 2013 May;34 Suppl 1:S175-7. doi:10.1007/s10072-013-1376-y; Volpe FM. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. J Clin Psychiatry. 2008 Sep;69(9):1449-54. doi:10.4088/jcp.v69n0912; Костюкова ЕГ, Мазо ГЭ, Мосолов СН и др. Биполярное аффективное расстройство. Клинические рекомендации. Взрослые. Электронное издание. Минздрав РФ. Москва; 2021. 245 с. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/675_1; Мосолов СН, Малин ДИ, Рывкин ПВ, Сычев ДА. Лекарственные взаимодействия препаратов, применяемых в психиатрической практике. Современная терапия психических расстройств. 2019;(S1):2-35. doi:10.21265/PSYPH.2019.50.40828

  4. 4
  5. 5
  6. 6
    Academic Journal

    Συνεισφορές: Казанский (Приволжский) федеральный университет

    Relation: ИТОГОВАЯ НАУЧНО-ПРАКТИЧЕСКАЯ КОНФЕРЕНЦИЯ ПРОФЕССОРСКО-ПРЕПОДАВАТЕЛЬСКОГО СОСТАВА ИНСТИТУТА ФИЗИКИ И ХИМИЧЕСКОГО ИНСТИТУТА ИМЕНИ А.М. БУТЛЕРОВА КАЗАНСКОГО ФЕДЕРАЛЬНОГО УНИВЕРСИТЕТА; http://dspace.kpfu.ru/xmlui/bitstream/net/175840/-1/F_ktk2022_148.pdf; https://dspace.kpfu.ru/xmlui/handle/net/175840; 543.64

  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
    Electronic Resource

    Additional Titles: Тревожно-депрессивные расстройства при болезни Паркинсона
    Тривожно-депресивні розлади при хворобі Паркінсона

    Πηγή: INTERNATIONAL NEUROLOGICAL JOURNAL; № 7.109 (2019); 43-49; МЕЖДУНАРОДНЫЙ НЕВРОЛОГИЧЕСКИЙ ЖУРНАЛ; МІЖНАРОДНИЙ НЕВРОЛОГІЧНИЙ ЖУРНАЛ; 2307-1419; 2224-0713

  14. 14
    Electronic Resource

    Additional Titles: Антидепрессанты в фокусе лекарственной токсикологии
    Антидепресанти у фокусі лікарської токсикології

    Πηγή: МЕДИЦИНА НЕВІДКЛАДНИХ СТАНІВ; № 2.57 (2014); 90-94; МЕДИЦИНА НЕОТЛОЖНЫХ СОСТОЯНИЙ; EMERGENCY MEDICINE; 2307-1230; 2224-0586